UBS lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares. The firm updated its forecast to reflect ongoing pressures in academic funding, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics Faces Market Challenges and Uncertainty, Leading to Hold Rating
- 10x Genomics price target lowered to $15 from $18 at Canaccord
- 10X Genomics Faces Mixed Outlook Amid Funding Uncertainties
- 10x Genomics price target lowered to $15 from $18 at Stifel
- 10x Genomics price target lowered to $11 from $15 at TD Cowen